A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
Price : $35 *
At a glance
- Drugs Tivantinib (Primary)
- Indications Liver cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.